Navigation Links
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
Date:3/30/2009

- Lorcaserin Very Well Tolerated Throughout Two-Year Study

- Conference Call Scheduled for Today at 8:30 a.m. EDT

SAN DIEGO, March 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Statistical significance (p<0.0001) was achieved on all three of the hierarchically ordered co-primary endpoints for patients treated with lorcaserin versus placebo. Treatment with lorcaserin was generally very well tolerated. An assessment of echocardiograms indicates no apparent drug-related effect on the development of US Food and Drug Administration (FDA)-defined valvulopathy over the two-year treatment period.

Primary Endpoint Analysis

The hierarchically ordered endpoints were the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Compared to placebo, using an intent-to-treat last observation carried forward (ITT-LOCF) analysis, treatment with lorcaserin was associated with highly statistically significant (p<0.0001) categorical and average weight loss from baseline after 12 months:

  • 47.5% of lorcaserin patients lost greater than or equal to 5% of their body weight from baseline compared to 20.3% in the placebo group. This result satisfies the efficacy benchmark in the most recent FDA draft guidance.
  • Average weight loss of 5.8% of body weight, or 12.7 pounds, was achieved in the
    '/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... acid compound, Johns Hopkins researchers have developed a two-pronged ... tests. The researchers cautioned that their double-punch molecule has ... they believe it represents a promising new strategy for ... long time, cancer researchers did not pay much attention ...
... eye procedures are safe and effective, according to results ... Academy of Ophthalmology’s //Joint Meeting. ,Researchers who examined ... say both procedures provide stable, long term improvement for ... those who doubt LASIK’s reliability, showing that both LASIK ...
... thousands of heart patients to have high-tech devices implanted ... the expensive devices are designed to shock damaged hearts ... death, which kills 300,000 Americans each year. ,But ... patients will benefit from their ICDs, a large number ...
... dinner last night, adding a large amount of fat – scientifically ... of us, that could be a big problem. // ... use it for energy. But patients with elevated levels of fat ... more likely to develop arthrosclerosis, or build-up of plaque in the ...
... way to reduce your risk for breast cancer, but a ... 2007 issue of Harvard Women’s Health Watch. Here are several ... Studies show that weight gain is a risk factor ... is believed to promote the development of breast cancer. Fat ...
... when reading a newspaper means holding it at ... //lens technology may offer a better solution, according ... of Ophthalmology’s 2006 Joint Meeting. ,According ... using wavefront technology offer significant improvements over standard ...
Cached Medicine News:Health News:Hybrid Molecule Causes Cancer Cells to Self-Destruct 2Health News:Hybrid Molecule Causes Cancer Cells to Self-Destruct 3Health News:PRK and LASIK Surgeries ‘Safe and Effective 2Health News:Are One-Third of Costly Implanted Heart Devices Unnecessary? 2Health News:Are One-Third of Costly Implanted Heart Devices Unnecessary? 3Health News:Sugars in Liver Found to Clear Fats from the Bloodstream 2Health News:Beyond Bifocals: Wavefront Technology Benefits Patients With Presbyopia 2
(Date:1/15/2014)... , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ... the very important aspects in today,s growth ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation ... expects to report results for the fourth quarter of ... announcing the results is scheduled for release after the ... ) Management will hold a conference call ... the fourth quarter and twelve months ended December 31, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ... states Dr Barnes. She goes on to state "my wish list ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... , DURHAM, N.C., Dec. ... , a portfolio company of Cato BioVentures, announces the ... its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy ... placebo controlled Phase 2 study investigated the effects of a ...
... NEW HAVEN, Conn., Dec. 8 Rib-X Pharmaceuticals, Inc., a ... drugs for the treatment of serious multi-drug-resistant infections, announced today ... University in the area of ribosome and antibiotic structure and ... high resolution crystal structure of new ribosome technology elucidated by ...
Cached Medicine Technology:Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 2Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 3Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology 2
The ideal on-the-spot reference for residents and practitioners seeking fast facts on fracture management....
Pocket Sports Medicine is the result of a collaboration between outstanding Editors and Contributors. The program covers the field so that both specialists and general orthopedists will find expert g...
Bones is a remarkable guide for the Medical Student, Nurse, Nurse Practitioner, Physician's Assistant or Physician to Bones....
The Urinary System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the urinary system....
Medicine Products: